The purpose of this study is to determine the use of 177Lu-PP-F11N for imaging and therapy of
patients with advanced medullary thyroid carcinoma (MTC). 177Lu-PP-F11N is a gastrin
analogon, binding to cholecystokinin-2 receptors. This receptors show an overexpression on
more than 90 % of medullary thyroid carcinomas.
In the pilot (phase 0) study we will correlate the tumour detection rate with the surgery and
histology (proof of concept study). Furthermore, kidney protection and dosimetry studies will
be performed in order to determine the kidney protection protocol and starting activity for
the dose escalation study in the following, dose escalation (phase I) study. In the phase I
study we will determinate the maximum tolerated dose of 177Lu-PP-F11N in patients with MTC.
Furthermore, correlation with tumour radiation dose and treatment response as well as organ
radiation doses and maximal tolerated dose will be performed in order to allow prospective
individual patient tailored therapy planning.